XTX501 Enters First Human Trial for Metastatic Lung Cancer
The Phase 1/2 trial tests a tumor-selective bispecific antibody designed to improve cytokine therapy tolerability.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe biotechnology companies should receive support for developing proprietary, masked immuno-oncology therapies?
Xilio Therapeutics has initiated a first-in-human Phase 1/2 clinical trial for XTX501, a bispecific antibody protein designed to treat metastatic non-small cell lung cancer. The study is currently in the research-stage, focusing on patients who have already undergone prior anti-PD(L)-1 therapy.
Why it matters
This trial tests whether a tumor-selective activation approach can improve the efficacy of IL-2 immunotherapies while avoiding the systemic toxicities that have historically limited their use. By masking the IL-2 component, the drug aims to concentrate immune activation specifically within the tumor microenvironment.
XTX501 is a PD-1/masked IL-2 bispecific antibody fusion protein. It functions by combining PD-1 inhibition with tumor-selective activation of IL-2, a cytokine that stimulates immune cell growth, to mitigate systemic side effects.
The players
Xilio Therapeutics
A Waltham-based biotech firm focused on developing tumor-selective immunotherapies using proprietary antibody-based platforms.
The details
The trial utilizes an open-label, multi-center design to evaluate the safety and tolerability of the drug as a monotherapy. XTX501 employs a 'masked' technology, a molecular shielding approach that keeps the immune-stimulating IL-2 inactive until it reaches the target tumor environment. This design is intended to prevent the non-specific immune activation that often causes dose-limiting toxicities in conventional IL-2 treatments.
Timeline
October 26, 2026: The first patient was dosed in the clinical trial.
November 4-8, 2026: The SITC 41st Annual Meeting takes place in Phoenix.
November 7, 2026: A trial-in-progress poster is scheduled for presentation.
Q4 2027: Initial Phase 1 clinical trial data is expected to be reported.
The Tech Race
The clinical evaluation of XTX501 joins a highly competitive field of bispecific protein engineering aimed at improving the therapeutic window of cytokine-based therapies. It marks a push to overcome the historical limitations of systemic IL-2 administration that have defined cancer immunotherapy research for decades.
This drug is in early-stage human testing and is not currently available for clinical use. Its development represents a potential future treatment pathway for patients with metastatic non-small cell lung cancer who have exhausted initial anti-PD(L)-1 therapy options.
The takeaway
The study attempts to resolve the toxicity trade-offs associated with IL-2 therapies by utilizing a selective activation mechanism. Stakeholders should monitor the Q4 2027 data readout to determine if the masked-protein design successfully improves patient tolerability.
What happens next
Xilio Therapeutics is set to present a trial-in-progress poster (abstract 542) on November 7, 2026, at the SITC 41st Annual Meeting in Phoenix.
Further reading
For more on the latest research in the field, explore the Biotech section.
More information
Track the study protocol and updates through the clinical trials government search portal.
Live Poll
Do you believe biotechnology companies should receive support for developing proprietary, masked immuno-oncology therapies?
